Drugs in R & D

, Volume 2, Issue 3, pp 178–183 | Cite as

Zanamivir

4-guanidino Neu5Ac2en, GG 167, GR 121167, GR 121167X, Relenza™
Section 1: Anti-Influenza Chemotherapy Adis R&D Profile
  • 4 Downloads

Keywords

Adis International Limited Influenza Virus Zanamivir Neuraminidase Inhibitor Rimantadine 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Ryan DM, Ticehurst J, Dempsey MH, et al. Inhibition of influenza virus replication in mice by GG167 (4-guanidino-2,4-dideoxy-2,3,-dehydro-N-acetylneuraminic acid) is consistent with extracellular activity of viral neuraminidase (sialidase). Antimicrob Agents Chemother 1994 Oct; 38: 2270–5PubMedCrossRefGoogle Scholar
  2. 2.
    Ryan DM, Ticehurst J, Dempsey MH. GG167 (4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid) is a potent inhibitor of influenza virus in ferrets. Antimicrob Agents Chemother 1995 Nov; 39: 2583–4PubMedCrossRefGoogle Scholar
  3. 3.
    Efthymiopoulos C, Barrington P, Patel J, et al. Pharmacokinetics of the neuraminidase inhibitor 4-guanidino Neu5Ac2en (GG167) following intravenous, intranasal and inhaled administration in man [abstract]. 34th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1994 Oct 4–7; Orlando, 265Google Scholar
  4. 4.
    Newman SP, Brown J, Pickford M, et al. Deposition pattern in the respiratory tract of the neuraminidase inhibitor zanamivir; a gamma scintigraphic study [abstract]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1997 Sep 28–Oct 1; Toronto, 237Google Scholar
  5. 5.
    Hayden F, Lobo M, Esinhart J, et al. Efficacy of 4-guanidino neu5Ac2en in experimental human influenza A virus infection. 34th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1994 Oct 4–7; Orlando, 190Google Scholar
  6. 6.
    Hayden FG, Osterhaus ADME, Treanor JJ, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. N Engl J Med 1997 Sep 25; 337: 874–80PubMedCrossRefGoogle Scholar
  7. 7.
    Webster A, Boyce M, Edmundson S, et al. Coadministration of orally inhaled zanamivir with inactivated trivalent influenza vaccine does not adversely affect the production of antihaemagglutinin antibodies in the serum of healthy volunteers. Clin Pharmacokinet 1999; 36 Suppl. 1: 51–8PubMedCrossRefGoogle Scholar
  8. 8.
    Woods JM, Bethell RC, Coates JAV, et al. 4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid is a highly effective inhibitor both of the sialidase (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitro. Antimicrob Agents Chemother 1993 Jul; 37: 1473–9PubMedCrossRefGoogle Scholar
  9. 9.
    Whittington A, Bethell R. Recent developments in the antiviral therapy of influenza. Expert Opin Ther Patents 5: 1995 Aug; 793–803CrossRefGoogle Scholar
  10. 10.
    Fenton RJ, Owens LJ, Morley PJ. Chemoprophylaxis of influenza A infections in mice and ferrets with neuraminidase inhibitors, exemplified by zanamivir (GG167). Antiviral Res 1998 Mar; 37: 72Google Scholar
  11. 11.
    Hayden FG, Rollins BS, Madren LK. Anti-influenza virus activity of the neuraminidase inhibitor 4-guanidino-Neu5Ac2en in cell culture and in human respiratory epithelium. Antiviral Res 1994 Oct; 25: 123–31PubMedCrossRefGoogle Scholar
  12. 12.
    Madren LK, Shipman Jr C, Hayden FG. In vitro inhibitory effects of combinations of anti-influenza agents. Antiviral Chem Chemother 1995 Mar; 6: 109–3Google Scholar
  13. 13.
    McKimm-Breschkin JL, Blick TJ, Sahasrabudhe A, et al. Generation and characterization of variants of NWS/G70C influenza virus after in vitro passage in 4-amino-neu5Ac2en and 4-guanidino-neu5Ac2en. Antimicrob Agents Chemother 1996 Jan; 40: 40–6PubMedGoogle Scholar
  14. 14.
    Colacino JM, Laver WG, Air GM. Selection of influenza A and B viruses for resistance to 4-guanidino-Neu5Ac2en in cell culture. J Infect Dis 1997 Aug; 176 Suppl. 1: S66–8CrossRefGoogle Scholar
  15. 15.
    Gubareva LV, Robinson MJ, Bethell RC, et al. Catalytic and framework mutations in the neuraminidase active site of influenza viruses that are resistant to 4-guanidino-Neu5Ac2en. J Virol 1997 May; 71: 3385–90PubMedGoogle Scholar
  16. 16.
    Barnett J, Dempsey M, Tisdale M, et al. Susceptibility monitoring of influenza virus clinical isolates to the neuraminidase inhibitor zanamivir (GG167) during phase II clinical efficacy trials [abstract]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1997 Sep 28–Oct 1; Toronto, 230Google Scholar
  17. 17.
    Schilling M, Povinelli L, Krause P, et al. Efficacy of zanamivir for chemoprophylaxis of nursing home influenza A outbreaks [abstract]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1997 Sep 28–Oct 1; Toronto, 230Google Scholar
  18. 18.
    Hayden FG, Treanor JJ, Betts RF, et al. Safety and efficacy of the neuraminidase inhibitor GG167 in experimental human influenza. JAMA 1996 Jan 24–31; 275: 295–9PubMedCrossRefGoogle Scholar
  19. 19.
    Monto AS, Robinson DP, Herlocher ML, et al. Zanamivir in the prevention of influenza among healthy adults: a randomized controlled trial. JAMA 1999 Jul 7; 282: 31–5PubMedCrossRefGoogle Scholar
  20. 20.
    Monto AS, Robinson DP, Griffin AD, et al. The effects of zanamivir on productivity in the prevention of influenza among healthy adults. J Antimicrob Chemother 1999 Jul; 44 Suppl. A: 41Google Scholar
  21. 21.
    MIST Study Group. Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. Lancet 1998 Dec 12; 352: 1877–81CrossRefGoogle Scholar
  22. 22.
    Faster relief from influenza symptoms for high risk and otherwise healthy patients with inhaled zanamivir [press release]. Biota Holdings Limited: 1998 Nov 17. Available from: URL: http://www.biota.com.au/press.htm [Accessed on 1999 Sep 1]
  23. 23.
    Osterhaus A, Tisdale M, Elliott M. A double blind randomized trial of zanamivir in the treatment of acute influenza — clinical and virological efficacy results [late-breaker abstracts]. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1998 Sep 24–27; San Diego, 11Google Scholar
  24. 24.
    Calfee DP, Peng AW, Cass LMR, et al. Protective efficacy of intravenous zanamivir in experimental human influenza [abstract]. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1998 Sep 24–27; San Diego, 332Google Scholar
  25. 25.
    Lalezari J, Klein T, Stapleton J, et al. The efficacy and safety of inhaled zanamivir in the treatment of influenza in otherwise healthy and high risk individuals in North America. J Antimicrob Chemother 1999 Jul; 44 Suppl. A: 42Google Scholar

Copyright information

© Adis International Limited 1999

Personalised recommendations